Regeneron And BioMed Realty Break Ground On A New 300,000 Square Foot R&D Build-to-Suit Facility In Westchester County, New

  Regeneron And BioMed Realty Break Ground On A New 300,000 Square Foot R&D
            Build-to-Suit Facility In Westchester County, New York

PR Newswire

SAN DIEGO, Oct. 28, 2013

SAN DIEGO, Oct. 28, 2013 /PRNewswire/ --Joined by  New York Senator Charles
E. Schumer and state, county and local government leaders, senior management
from Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and BioMed Realty Trust,
Inc. (NYSE: BMR) broke ground today on a new 300,000 square foot build-to-suit
research facility for Regeneron at BioMed Realty's The Landmark at Eastview
campus in Westchester County, New York. Employees from both companies gathered
for the groundbreaking ceremony at the site. Featured speakers at the ceremony
were Senator Schumer; Leonard S. Schleifer, M.D., Ph.D., Founder, President
and Chief Executive Officer of Regeneron; George D. Yancopoulos, Chief
Scientific Officer and President, Regeneron Laboratories; Alan D. Gold,
Chairman and Chief Executive Officer of BioMed Realty; U.S. Congresswoman Nita
Lowey of New York; Rob Astorino, Westchester County Executive; and Kenneth
Adams, President and CEO of the Empire State Development Corporation.

"We are pleased to be celebrating this groundbreaking with distinguished civic
leaders and especially with our employees here in Westchester, our home since
our first lab opened on this site in 1989," said Dr. Schleifer of Regeneron.
"As Regeneron further expands its scientific discovery programs, advances new
therapies and commercializes our robust development pipeline, Westchester
County and The Landmark at Eastview continue to offer an optimal campus
environment for our employees and to facilitate our growth. This new facility
will include design features to further propel our drug discovery and
development forward and leverage the expertise of our real estate partner,
BioMed Realty, which has supported our business since 2004 through a
combination of new construction, adaptive re-use of different spaces and
collaborative on-site management."

Mr. Gold of BioMed Realty remarked,"We are proud to stand with Regeneron
today to break ground on the site of our latest expansion of a truly
extraordinary relationship. The Regeneron story continues to inspire all of us
at BioMed Realty, especially here at The Landmark. We congratulate them on
being named last week the world's number one biopharmaceutical employer by
Science magazine for the second consecutive year. Their success is a great
testimony to Len, George, and all of the now 2,200 employees throughout

The new state-of-the-art facility is located entirely at the 116-acre Landmark
campus that sits in the Towns of Greenburgh and Mt. Pleasant in Westchester
County. Upon completion of construction, Regeneron will lease and fully occupy
for a 15-year term the to-be-built laboratory and office space adjacent to its
other Landmark facilities. BioMed Realty estimates that the new buildings will
be occupied by Regeneron in late 2015.

About BioMed Realty Trust

BioMed Realty, with its trusted expertise and valuable relationships, delivers
optimal real estate solutions for biotechnology and pharmaceutical companies,
scientific research institutions, government agencies and other entities
involved in the life science industry. BioMed Realty owns or has interests in
properties comprising approximately 16.2 million rentable square feet.
Additional information is available at

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: risks and uncertainties
affecting property development and construction, including the development
project at The Landmark at Eastview campus for Regeneron Pharmaceuticals;
general risks affecting the real estate industry (including, without
limitation, the inability to enter into or renew leases, dependence on
tenants' financial condition, and competition from other developers, owners
and operators of real estate); adverse economic or real estate developments in
the life science industry or the company's target markets; risks associated
with the availability and terms of financing, the use of debt to fund
acquisitions, developments and other investments, and the ability to refinance
indebtedness as it comes due; failure to maintain the company's investment
grade credit ratings with the ratings agencies; failure to manage effectively
the company's growth and expansion into new markets, or to complete or
integrate acquisitions and developments successfully; reductions in asset
valuations and related impairment charges; risks associated with tax credits,
grants and other subsidies to fund development activities; risks associated
with downturns in foreign, domestic and local economies, changes in interest
rates and foreign currency exchange rates, and volatility in the securities
markets; ownership of properties outside of the United States that subject the
company to different and potentially greater risks than those associated with
the company's domestic operations; risks associated with the company's
investments in loans, including borrower defaults and potential principal
losses; potential liability for uninsured losses and environmental
contamination; risks associated with the company's potential failure to
qualify as a REIT under the Internal Revenue Code of 1986, as amended, and
possible adverse changes in tax and environmental laws; and risks associated
with the company's dependence on key personnel whose continued service is not
guaranteed. For a further list and description of such risks and
uncertainties, see the reports filed by the company with the Securities and
Exchange Commission, including the company's most recent annual report on Form
10-K and quarterly reports on Form 10-Q. The company disclaims any intention
or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.

Contact: Rick Howe, Senior Director, Corporate Communications, (858) 207-5859,
Press spacebar to pause and continue. Press esc to stop.